These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Takahashi A; Nagashima K; Hamasaki A; Kuwamura N; Kawasaki Y; Ikeda H; Yamada Y; Inagaki N; Seino Y Diabetes Res Clin Pract; 2007 Sep; 77(3):343-50. PubMed ID: 17316868 [TBL] [Abstract][Full Text] [Related]
3. Antidiabetic sulfonylurea stimulates insulin secretion independently of plasma membrane KATP channels. Geng X; Li L; Bottino R; Balamurugan AN; Bertera S; Densmore E; Su A; Chang Y; Trucco M; Drain P Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E293-301. PubMed ID: 17405830 [TBL] [Abstract][Full Text] [Related]
4. Hyperinsulinism in mice with heterozygous loss of K(ATP) channels. Remedi MS; Rocheleau JV; Tong A; Patton BL; McDaniel ML; Piston DW; Koster JC; Nichols CG Diabetologia; 2006 Oct; 49(10):2368-78. PubMed ID: 16924481 [TBL] [Abstract][Full Text] [Related]
5. Iptakalim, a vascular ATP-sensitive potassium (KATP) channel opener, closes rat pancreatic beta-cell KATP channels and increases insulin release. Misaki N; Mao X; Lin YF; Suga S; Li GH; Liu Q; Chang Y; Wang H; Wakui M; Wu J J Pharmacol Exp Ther; 2007 Aug; 322(2):871-8. PubMed ID: 17522344 [TBL] [Abstract][Full Text] [Related]
6. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685 [TBL] [Abstract][Full Text] [Related]
7. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT; N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550 [TBL] [Abstract][Full Text] [Related]
8. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014 [TBL] [Abstract][Full Text] [Related]
9. Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement. Muñoz A; Hu M; Hussain K; Bryan J; Aguilar-Bryan L; Rajan AS Endocrinology; 2005 Dec; 146(12):5514-21. PubMed ID: 16123162 [TBL] [Abstract][Full Text] [Related]
10. Impaired glucose-stimulated insulin secretion and reduced β-cell mass in pancreatic islets of hyperthyroid rats. Karbalaei N; Noorafshan A; Hoshmandi E Exp Physiol; 2016 Aug; 101(8):1114-27. PubMed ID: 27060234 [TBL] [Abstract][Full Text] [Related]
11. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences. Flechtner I; de Lonlay P; Polak M Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510 [TBL] [Abstract][Full Text] [Related]